Works matching IS 0278-0232 AND VI 40 AND IP 2 AND DT 2022

Results: 20

Salvage therapy with "Dara‐KDT‐P(A)CE" in heavily pretreated, high‐risk, proliferative, relapsed/refractory multiple myeloma.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 202, doi. 10.1002/hon.2949
By:
- Zhou, Xiang;
- Ruckdeschel, Anna;
- Peter, Jessica;
- Böckle, David;
- Hornburger, Hannah;
- Danhof, Sophia;
- Steinhardt, Maximilian Johannes;
- Heimeshoff, Larissa;
- Einsele, Hermann;
- Kortüm, Klaus Martin;
- Rasche, Leo
Publication type:
Article
SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 287, doi. 10.1002/hon.2957
By:
- Abid, Muhammad Abbas;
- Abid, Muhammad Bilal
Publication type:
Article
Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 172, doi. 10.1002/hon.2956
By:
- Cao, Di;
- Cao, Xia;
- Jiang, Yu;
- Xu, Juan;
- Zheng, Yuhuan;
- Kang, Deying;
- Xu, Caigang
Publication type:
Article
First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 297, doi. 10.1002/hon.2953
By:
- Mozas, Pablo;
- Rivero, Andrea;
- Rivas‐Delgado, Alfredo;
- Correa, Juan Gonzalo;
- Condom, Maria;
- Nadeu, Ferran;
- Giné, Eva;
- Delgado, Julio;
- Villamor, Neus;
- Campo, Elías;
- Magnano, Laura;
- López‐Guillermo, Armando
Publication type:
Article
Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 181, doi. 10.1002/hon.2947
By:
- Tissino, Erika;
- Pivetta, Eliana;
- Capuano, Alessandra;
- Capasso, Guido;
- Bomben, Riccardo;
- Caldana, Chiara;
- Rossi, Francesca Maria;
- Pozzo, Federico;
- Benedetti, Dania;
- Boldorini, Renzo;
- Gaidano, Gianluca;
- Rossi, Davide;
- Zamò, Alberto;
- Hartmann, Tanja Nicole;
- Doliana, Roberto;
- Colombatti, Alfonso;
- Gattei, Valter;
- Spessotto, Paola;
- Zucchetto, Antonella
Publication type:
Article
Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 280, doi. 10.1002/hon.2974
By:
- Weinbergerová, Barbora;
- Demel, Ivo;
- Víšek, Benjamin;
- Válka, Jan;
- Čerňan, Martin;
- Jindra, Pavel;
- Novák, Jan;
- Stejskal, Lukáš;
- Kovácsová, Flóra;
- Kabut, Tomáš;
- Szotkowski, Tomáš;
- Hájek, Roman;
- Žák, Pavel;
- Cetkovský, Petr;
- Král, Zdeněk;
- Mayer, Jiří
Publication type:
Article
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 191, doi. 10.1002/hon.2969
By:
- Belyaeva, Elizaveta;
- Rubenstein, Ayelet;
- Pierson, Sheila K.;
- Dalldorf, Delaney;
- Frank, Dale;
- Lim, Megan S.;
- Fajgenbaum, David C.
Publication type:
Article
Sinonasal B‐cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 160, doi. 10.1002/hon.2968
By:
- Eriksen, Patrick R. G.;
- Clasen‐Linde, Erik;
- Nully Brown, Peter de;
- Haunstrup, Laura;
- Christoffersen, Mette;
- Asdahl, Peter;
- Thomsen, Troels Møller;
- Harwood, Cecilie Dupont;
- Heegaard, Steffen;
- Buchwald, Christian von
Publication type:
Article
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 269, doi. 10.1002/hon.2964
By:
- Brackman, Deanna;
- Eckert, Doerthe;
- Menon, Rajeev;
- Salem, Ahmed Hamed;
- Potluri, Jalaja;
- Smith, B. Douglas;
- Wei, Andrew H.;
- Hayslip, John;
- Miles, Dale;
- Mensing, Sven;
- Gopalakrishnan, Sathej;
- Zha, Jiuhong
Publication type:
Article
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T‐cell lymphoma: A FIL phase 2 study.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 307, doi. 10.1002/hon.2963
By:
- Stefoni, Vittorio;
- Pellegrini, Cinzia;
- Argnani, Lisa;
- Corradini, Paolo;
- Dodero, Anna;
- Orsucci, Lorella;
- Volpetti, Stefano;
- Zinzani, Pier Luigi
Publication type:
Article
Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 243, doi. 10.1002/hon.2961
By:
- Bujarski, Sean;
- Sutanto, Christine;
- Spektor, Tanya M.;
- To, Jennifer;
- Swift, Regina A.;
- Green, Tracy;
- Eades, Benjamin R.;
- Emamy‐Sadr, Marsiye;
- Souther, Eric;
- Berenson, James R.
Publication type:
Article
Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 233, doi. 10.1002/hon.2959
By:
- Das, Avash;
- Dasgupta, Subhajit;
- Gong, Yan;
- Shah, Urvi A.;
- Fradley, Michael G.;
- Cheng, Richard K.;
- Roy, Bhaskar;
- Guha, Avirup
Publication type:
Article
Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 223, doi. 10.1002/hon.2958
By:
- Li, Wei;
- Liu, Meijing;
- Yuan, Ting;
- Yan, Lixiang;
- Cui, Rui;
- Deng, Qi
Publication type:
Article
CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 258, doi. 10.1002/hon.2951
By:
- Liao, Xiong‐yu;
- Fang, Jian‐pei;
- Zhou, Dun‐hua;
- Qiu, Kun‐yin
Publication type:
Article
Differential transcriptomic profiling in ibrutinib‐naïve versus ibrutinib‐resistant Richter syndrome.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 302, doi. 10.1002/hon.2950
By:
- Wang, Hanyin;
- Tian, Shulan;
- Zhao, Qing;
- Blumenschein, Wendy;
- Yearley, Jennifer H.;
- Secreto, Charla R.;
- Sinha, Sutapa;
- Call, Timothy G.;
- Wang, Yucai;
- Parikh, Sameer A.;
- Kenderian, Saad S.;
- He, Rong;
- Leis, Jose F.;
- Shi, Min;
- Van Dyke, Daniel L.;
- Kay, Neil E.;
- Slager, Susan L.;
- Braggio, Esteban;
- Yan, Huihuang;
- Ding, Wei
Publication type:
Article
Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 212, doi. 10.1002/hon.2955
By:
- Shang, Yufeng;
- Jin, Yanxia;
- Liu, Hailing;
- Ding, Lu;
- Tong, Xiqin;
- Tu, Honglei;
- Zang, Longkai;
- Lin, Chenyao;
- Hu, Jinsong;
- Zhou, Fuling
Publication type:
Article
Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre‐CAR T‐cell era.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 292, doi. 10.1002/hon.2952
By:
- Mathys, Anina;
- Bacher, Ulrike;
- Banz, Yara;
- Legros, Myriam;
- Mansouri Taleghani, Behrouz;
- Novak, Urban;
- Pabst, Thomas
Publication type:
Article
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 129, doi. 10.1002/hon.2943
By:
- Eyre, Toby A.;
- Hori, Satoshi;
- Munir, Talha
Publication type:
Article
Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T‐cell acute lymphoblastic leukemia.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 249, doi. 10.1002/hon.2948
By:
- Yuan, Tian;
- Wang, Jinhuan;
- Shi, Ce;
- Wang, Yi;
- Xia, Bing;
- Xu, Wen;
- Yang, Hongliang;
- Yang, Yaling;
- Ye, Matthew T.;
- Khalid, Samah;
- Liang, Yong;
- Tian, Chen;
- You, M. James;
- Wang, Yafei
Publication type:
Article
Issue Information.
Published in:
Hematological Oncology, 2022, v. 40, n. 2, p. 127, doi. 10.1002/hon.2890
Publication type:
Article